Clinical Manifestations and Long‐Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America
Open Access
- 25 May 2021
- journal article
- research article
- Published by Wiley in ACR Open Rheumatology
- Vol. 3 (6), 404-412
- https://doi.org/10.1002/acr2.11263
Abstract
Objective To describe clinical manifestations and outcomes in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in North America. Methods Analysis of patients aged 18 years or older who fulfilled the 1990 American College of Rheumatology Classification Criteria for EGPA enrolled in the Vasculitis Clinical Research Consortium from 2003 to 2019. Main clinical characteristics, treatments, outcomes, and accumulated damage were studied. Results The cohort included 354 patients; 59% female; age at diagnosis of 50.0 (±14) years; 39% were antineutrophil cytoplasm antibody (ANCA) positive. Time from diagnosis to last follow-up was 7.0 (±6.2) years; 49.4% had one or more relapse. Patients positive for ANCA more commonly had neurological and kidney involvement when compared with patients negative for ANCA, who had more cardiac and lung manifestations. At last study visit, only 35 (12.6%) patients had been off all therapy for more than 2 years during their follow-up. The overall mortality rate was 4.0% and did not differ by ANCA status or cyclophosphamide use. Scores on the Vasculitis Damage Index (VDI) for 134 patients with two or more visits and more than 1 year of follow-up increased from 1.7 (±1.8) at enrollment (3.7 [±5.1] years after diagnosis) to 3.35 (±2.1) at last follow-up (7.5 [±5.8] years after diagnosis), mainly represented by chronic asthma (67.5%), peripheral neuropathy (49.6%), and chronic sinusitis (31.3%). Longer duration of glucocorticoid use and relapse were associated with higher VDI scores. Conclusion This analysis describes the many clinical manifestations and varied outcomes of EGPA and highlights the ongoing need to attain more sustained, long-term remission to limit the accrual of disease-related damage.Keywords
Funding Information
- National Center for Research Resources (U54 RR019497)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54 AR057319)
- GlaxoSmithKline
- National Center for Advancing Translational Sciences
This publication has 32 references indexed in Scilit:
- A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patientsAnnals Of The Rheumatic Diseases, 2012
- The Five-Factor Score RevisitedMedicine, 2011
- Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment IndexAnnals Of The Rheumatic Diseases, 2010
- Churg–Strauss syndrome: evidence for disease subtypes?Current Opinion in Rheumatology, 2010
- Churg–Strauss syndromeCurrent Opinion in Rheumatology, 2007
- Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg‐Strauss syndromeArthritis & Rheumatism, 2005
- What is known about the epidemiology of the vasculitides?Best Practice & Research Clinical Rheumatology, 2005
- Epidemiology of systemic vasculitis: A ten-year study in the United KingdomArthritis & Rheumatism, 2000
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992
- The American College of Rheumatology 1990 criteria for the classification of churg‐strauss syndrome (allergic granulomatosis and angiitis)Arthritis & Rheumatism, 1990